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Abstract
AIM: To investigate the association between epidermal 
growth factor (EGF) +61A/G polymorphism and suscep-
tibility to gastric cancer, through a cross-sectional study.
METHODS: Polymerase chain reaction resctriction frag-
ment lenght polymorphism analyses were used to geno-
type EGF +61 in 207 patients with gastric lesions (162 
patients with gastric adenocarcinomas, 45 with atrophy 
or intestinal metaplasia) and 984 controls. All subjects 
were Caucasian. 
RESULTS: Genotype distribution was 23.5% for GG and 
76.5% for GA/AA in the control group, 18.4% for GG 
and 68.6% for GA/AA in the entire group with gastric 
lesions and 17.9% for GG and 82.1% for GA/AA in the 
group with gastric adenocarcinoma. No statistically sig-
nificant associations were found between EGF +61 vari-
ants and risk for developing gastric cancer [odds ratios 
(OR) = 1.41, 95% confidence intervals (CI): 0.90-2.21, 
P = 0.116]. However, the stratification of individuals 
by gender revealed that males carrying A alleles (EGF 
+61A/G or AA) had an increased risk for developing 
gastric cancer as compared to GG homozygous males 
(OR = 1.55, 95% CI: 1.05-2.28, P = 0.021). 
CONCLUSION: In summary, we found that males who 
were A carriers for EGF +61 had an increased risk for 
developing gastric cancer. This result may be explained 
by the suggestion that women secrete less gastric acid 
than men.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
Growth factors activate the complex processes of  cellular 
signalling, promoting cell changes[1,2]. They are “positive 
signals” in the cell and are regulated by “negative signals” 
which control amplitude and duration[2]. The balance be-
tween these signals is all-important in cell homeostasis[2]. 
Epidermal growth factor (EGF) performs a key role in 
promoting cell survival[3]. After binding to its receptor 
(EGFR), it induces a signalling cascade that culminates in 
change of  gene transcription[3-5]. EGFR signalling is not 
only important in cellular proliferation but also contrib-
utes to several other cellular processes involved in cancer 
progression, including angiogenesis, metastatic spread, 
and inhibition of  apoptosis[6].
EGFR (also known as ErbB1) belongs to the family of  
ErbB (from avian erythroblastic leukaemia viral oncogene 
homologue) receptors which are involved in the develop-
ment of  several human cancers[7]. The increase in EGFR 
signalling may be caused by overexpression of  EGFR, 
increased concentration of  ligand(s) (through autocrine/
paracrine processes), the presence of  aberrant receptors 
due to gene alteration, and alterations in molecules that 
control receptor signalling output[6,8]. EGFR and ErbB-2 
are frequently overexpressed in gastric carcinomas[9].
EGF gene has a polymorphism in position +61 which 
consists of  the substitution of  adenine (A) for guanine (G). 
AA genotype carriers have lower levels of  EGF expres-
sion than individuals with the GG or AG genotypes[10]. 
Ethnic differences in the distribution of  the EGF gene 
have been reported, and several studies have been carried 
out regarding the role of  EGF genotypes in susceptibility 
to gastric cancer in Asian populations and in other organs.
In this cross-sectional study we analysed the associa-
tion between this EGF polymorphism and the risk for 
gastric cancer in a high incidence Caucasian population.
MATERIALS AND METHODS
Subjects
This cross-sectional study was performed in 1191 indi-
viduals, including 207 patients histologically diagnosed 
with gastric lesions followed at the Portuguese Institute of  
Oncology-Porto (IPO-P), and a control group of  984 indi-
viduals without cancer disease history, all from the north-
ern region of  Portugal. All individuals provided informed 
consent according to the Declaration of  Helsinki, and the 
patients in both groups were of  Caucasian ethnicity.
Patients were further divided according to the type of  
lesions at histopathological diagnosis following multiple 
endoscopic biopsies. Patients included those who dis-
played lesions such as high-grade dysplasia and intestinal-
type invasive gastric adenocarcinoma (n = 162) and pa-
tients with non-dysplastic lesions associated with gastric 
adenocarcinoma such as atrophy or intestinal metaplasia 
(n = 45), who had received standardized follow-up since 
2001. The group of  patients with gastric adenocarcinoma 
included 73 females and 89 males (55%) with a median 
age at diagnosis of  54 years (mean 54.3 years, standard de-
viation 11.8 years), and the group of  patients with atrophy 
or intestinal metaplasia included 25 females and 20 males 
(44%) with a median age at diagnosis of  59 years (mean 
59.7 years, standard deviation 10.8 years).
The control subjects included 524 females and 460 males 
(46.7%) randomly recruited from the Blood Donor Bank of  
IPO-P and Hospital de S. Marcos, Braga, and had no cur-
rent or history of  neoplastic disease. The median age was 45 
years (mean 46.2 years, standard deviation 11.1 years). 
DNA was extracted from peripheral blood samples 
obtained by a standard venipuncture technique using 
EDTA-containing tubes, as previously described in stud-
ies from our group[11,12].
EGF +61A/G genotype analysis
The +61A/G polymorphism was genotyped by PCR-
RFLP (polymerase chain reaction-restriction fragment 
length polymorphism) analysis, as previously described[10]. 
Briefly, amplification was carried out in a 50 μL reac-
tion mixture containing: 1 × Taq Buffer, 1.5 mmol/L 
of  MgCl2, 0.2 mmol/L of  dNTPs, 0.3 μmol/L of  each 
primer and 1U Taq DNA polymerase. The cycling condi-
tions were: 95℃ for 5 min, followed by 35 amplification 
cycles at 94℃ for 60 s, 55℃ for 60 s and 72℃ for 60 s, 
followed by one elongation step at 72℃ for 5 min. A 
242 base pair (bp) fragment was amplified using prim-
ers: F-5'TGTCACTAAAGGAAAGGAGGT3' and 
R-5'TTCACAGAGTTTAACAGCCC3'. The A61G varia-
tion was identified with the restriction enzyme AluⅠ. 
Two units of  restriction enzyme were added to 10 μL of  
PCR products in a final volume of  15 μL. The incubation 
was performed at 37℃ overnight. The products were sep-
arated on 3% agarose gels with 0.5% ethidium bromide 
and photographed under UV illumination. 
After destruction of  the recognition site by the re-
striction enzyme, the A allele produced 4 fragments: 15, 
34, 91 and 102 bp, while the G allele produced 3 frag-
ments: 15, 34 and 193 bp. In the gel only fragments 91, 
102 and 193 bp were visible.
Statistical analysis
The computer software SPSS for Windows (version 15.0) 
and Epi Info (version 6.04) were used for all statistical 
analyses. The χ2 test was used to compare differences be-
tween categorical variables, and verify that the observed 
allele distribution in the control group was in Hardy-
Weinberg equilibrium. A 5% level of  significance was used 
in the analysis. Odds ratios (OR) and 95% confidence 
intervals (CI) were calculated to assess the relationship be-
tween the polymorphic variants and gastric lesions. 
RESULTS
The frequencies of  EGF genotypes in the gastric lesions 
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group and the control group are presented in Table 1. The 
frequencies were 23.5% for GG and 76.5% for GA/AA 
in the control group, 18.4% for GG and 68.6% for GA/
AA in the entire group with gastric lesions and 17.9% for 
GG and 82.1% for GA/AA in the group with gastric ad-
enocarcinoma. As shown in Table 1, no increased risk of  
developing non-tumor gastric lesions (P = 0.109) or gas-
tric adenocarcinoma (P = 0.116) was found for individuals 
who carried the A allele.
When adjustments were made for allele genotype and 
sex, we found that males who were A carriers had an in-
creased risk of  developing gastric cancer in comparison to 
females (OR = 1.55, 95% CI: 1.05-2.28, P = 0.021) (Table 2).
No other associations were found for the other char-
acteristics tested.
DISCUSSION
The EGF protein is a growth factor that activates signal 
transduction pathways promoting proliferation, migration 
and differentiation[13]. In particular, EGF is involved in 
regulating proliferation of  mucosal cells in the gastroin-
testinal tract, stimulating mucus production, and inhibiting 
gastric secretion[14,15]. However, in gastric cancer, EGF dis-
plays oncogenic properties[16,17], and its overexpression is 
correlated with deep invasion, advanced malignancy stage, 
and poor patient prognosis[18].
In this cross-sectional study, we analysed the associa-
tion between a functional polymorphism of  the EGF 
gene (+61 A/G) and the risk for developing gastric can-
cer. Our data showed a statistically significant increased 
risk for developing gastric cancer in males who were A 
carriers (OR = 1.55, 95% CI: 1.05-2.28, P = 0.021); how-
ever, no statistically significant differences were found 
when the entire cancer group was considered (male and 
female gastric adenocarcinoma patients, P = 0.116). 
Salomon et al[9] reported that EGFR is overexpressed 
in 33% of  gastric adenocarcinomas, compared to only 
3.8% in the early stages of  gastric carcinoma development 
or in non-malignant specimens. Nevertheless, EGFR 
expression was more frequent in well-differentiated ad-
vanced stage adenocarcinomas, and EGFR immunoreac-
tivity was significantly higher in tumor stages Ⅲ and Ⅳ 
as well as in metastatic carcinomas[9]. EGF and EGFR are 
expressed at a frequency of  42% and 41%, respectively, 
in poorly differentiated gastric carcinomas, and most fre-
quently in tumors greater than 6 cm in size[9]. Although 
EGF and EGFR are associated with poor prognosis, less 
than half  of  gastric tumors have expression or overex-
pression of  these proteins. 
In our study, the most interesting result was the in-
creased risk for gastric cancer in male patients. A sexual di-
morphism in gastric acid secretion has been reported, with 
females secreting less gastric acid (approximately 40%) than 
males[19]. The mechanisms mediating this difference are un-
known, but a role for oestrogens has been suggested which 
may inhibit gastric acid secretion through two oestrogen 
receptor (ER) subtypes present in the stomach[19]. EGF 
decreases FSH (follicle-stimulating hormone) and particu-
larly inhibits the expression of  hormones produced in the 
ovary (oestrogen and progesterone), acting in the evolution 
of  ovarian follicles[20-26]. Therefore, in females with a lower 
expression of  EGF (A carriers) we may consider that stom-
ach cells may receive less information to proliferate. Nev-
ertheless, in G carriers (with greater expression of  EGF), 
the differences between genders are not significant, and 
according to our previous studies it is proposed that EGFR 
expression may be lower in G carriers, because EGF is 
involved in internalization of  EGFR[27,28]. However, more 
work is required to elucidate the correct mechanism.
Others studies regarding the association between 
gastric cancer and EGF polymorphism in Asian popula-
tions have been reported[29-31]. Hamai et al[29] and Jin et al[30] 
associated A carriers with a lower risk of  developing 
gastric cancer. However, Goto et al[31] did not find any dif-
ferences between this polymorphism and gastric cancer. 
When analyzing the frequency of  EGF +61 genotypes 
among these reports, one can observe that Asians present 
a significant difference in comparison to Caucasians (our 
study), namely in AA and GG genotypes (Table 3). In our 
results, the frequency of  EGF genotypes in the control 
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Table 1  Associations between EGF  +61A/G variants and 
clinicopathological parameters in patients with gastric lesions1 
n  (%)
Cases Controls OR (95% CI) P
Gastric lesions1 (n = 207)
Genotypes
GG   38 (18.4) 231 (23.5) 1
GA 104 (50.2) 449 (45.6) 1.41 (0.92-2.15) 0.096
AA   65 (31.4) 304 (30.9) 1.30 (0.82-2.06) 0.237
GA + AA 169 (68.6) 753 (76.5) 1.36 (0.92-2.04) 0.109
Atrophy or intestinal metaplasia (n = 45)
Genotypes
GG     9 (20.0) 231 (23.5) 1
GA   20 (44.4) 449 (45.6) 1.44 (0.49-2.76) 0.743
AA   16 (35.6) 304 (30.9) 1.35 (0.55-3.37) 0.478
GA + AA   36 (80.0) 753 (76.5) 1.23 (0.56-2.78) 0.590
Gastric adenocarcinoma (n = 162)
Genotypes
GG   29 (17.9) 231 (23.5) 1
GA   84 (51.9) 449 (45.6) 1.49 (0.93-2.40) 0.082
AA   49 (30.2) 304 (30.9) 1.28 (0.77-2.16) 0.317
GA + AA 133 (82.1) 753 (76.5) 1.41 (0.90-2.21) 0.116
1Gastric lesions: atrophy or intestinal metaplasia and gastric adenocarci-
noma. OR: Odds ratios; CI: Confidence intervals.
Table 2  Associations between EGF  +61A/G variants and 
gender
Controls Cases OR (95%CI) P
GG M 117 14 1
F 114 15 1.04 (0.45-2.41) 0.913
AA/AG M 343 75 1
F 410 58 0.65 (0.44-0.95) 0.021
OR: Odds ratios; CI: Confidence intervals.
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population was in agreement with other published stud-
ies with Caucasians populations[10,32-34]. Two recent meta-
analyses have discussed the role of  EGF polymorphism 
in susceptibility to cancer[35,36]. Future studies may confirm 
these results with adjustment for non-genetic putative risk 
factors for gastric cancer (ex: smoking, alcohol consump-
tion, social class or H. pylori).
In conclusion, we found that female patients who 
were A carriers of  EGF +61A/G had a decreased risk of  
developing gastric cancer. Furthermore, it has been sug-
gested that women secrete less gastric acid than men[19], 
which is consistent with our hypothesis that different ef-
fects of  EGF +61A/G variants may occur in males and 
females in relation to gastric cancer risk.
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